Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers.

ABSTRACT: RNA Interference (RNAi) has brought revolutionary transformations in cancer management in the past two decades. RNAi-based therapeutics including siRNA and shRNA have immense scope to silence the expression of mutant cancer genes specifically in a therapeutic context. Although tremendous progress has been made to establish catalytic RNA as a new class of biologics for cancer management, a lot of extracellular and intracellular barriers still pose a long-lasting challenge on the way to clinical approval. A series of chemically suitable, safe and effective viral and non-viral carriers have emerged to overcome physiological barriers and ensure targeted delivery of RNAi. The newly invented carriers, delivery techniques and gene editing technology made current treatment protocols stronger to fi

SUBMITTER: Karim ME 

PROVIDER: S-EPMC6026921 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature